Watson Pharmaceuticals, Inc. a leading specialty pharmaceutical company, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.

Dronabinol is the generic version of Solvay Pharmaceuticals' MARINOL(R) (dronabinol) CIII Capsules, indicated to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol is also indicated to treat anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). For the 12-months ending December 2007, Solvay reported MARINOL(R) sales of 105 million

Under the terms of the supply agreement, Solvay Pharmaceuticals will supply the dronabinol capsules to the Company's subsidiary, Watson Pharma, which will market, sell and distribute the product in the United States. Solvay Pharmaceuticals will receive a share of the profits from Watson's sales of the generic product in the U.S. market. Further details on the agreement have not been disclosed.

Dronabinol should not be used by any patient who has a history of hypersensitivity to any cannabinoid or to sesame oil. Patients should not drive, operate machinery, or engage in hazardous activity until they establish that they can tolerate dronabinol and perform such tasks safely.

Dronabinol should be used with caution in patients with a history of seizure disorder; patients with cardiac disorders; patients with a history of substance abuse (including alcohol abuse or dependence); patients with mania, depression, or schizophrenia (along with careful psychiatric monitoring); patients taking sedatives, hypnotics, or other psychoactive drugs; and in elderly patients, pregnant patients, nursing mothers, or pediatric patients. The most common side effects probably related to dronabinol are dizziness, feelings of exaggerated happiness, paranoid reaction, drowsiness, thinking abnormal, abdominal pain, nausea and vomiting.